CCFIB

Cardiac Control of Fear in Brain

Coordinatore	UNIVERSITY OF SUSSEX    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	1˙912˙383 €
EC contributo	1˙912˙383 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2012-ADG_20120411
Funding Scheme	ERC-AG
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-06-01   -   2017-05-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY OF SUSSEX  Organization address address: Sussex House city: FALMER, BRIGHTON postcode: BN1 9RH contact info Titolo: Ms. Nome: Tina Cognome: Lehmbeck Email: send email Telefono: +44 1273 877960 Fax: +44 1273 678192	UK (FALMER, BRIGHTON)	hostInstitution	1˙912˙383.00
2	UNIVERSITY OF SUSSEX  Organization address address: Sussex House city: FALMER, BRIGHTON postcode: BN1 9RH contact info Titolo: Prof. Nome: Hugo Dyfrig Cognome: Critchley Email: send email Telefono: +44 1273 678336 Fax: +44 1273 678192	UK (FALMER, BRIGHTON)	hostInstitution	1˙912˙383.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Imagine what might be possible if you can turn fear on and off. In exploring the contribution of bodily arousal to emotions, we uncovered a specific mechanism whereby the brain’s processing of threatening / fear stimuli is ‘gated’ by the occurrence of heartbeats: Fear stimuli presented when the heart has just made a beat are processed more effectively than at other times, modulating their emotional impact. We term this effect the Cardiac Control of Fear in Brain (CCFIB). Specifically, I wish to refine, develop and exploit CCFIB as; 1) a clinical screening tool for drugs and patients; 2) as the basis of an intervention to accelerate unlearning of fear, e.g. for treatment of anxiety disorders; 3) as a means to optimise and enrich human-machine interactions, in anticipation of the rapid development of virtual or augmented reality (VR/AR) as a therapeutic tool, and to open possibilities for improving machine operation. This ground-breaking project will have impact in many areas, notably in the clinical management of anxiety disorders, which affect 69.1 million European Union citizens at an annual cost of €74.4 billion, and in the educational, recreational and occupational realms of human-machine interaction. The proposal 1) will refine knowledge about the neurochemistry and stimulus-specificity of CCFIB for implementation as a clinical screening tool, using pharmacological and neuroimaging methods. 2) Test in clinical anxiety patients the power of CCFIB to predict symptom profile and response to psychological and pharmacological treatment. 3) Optimize CCFIB to augment psychological and behavioural treatments and validate this in phobic individuals. 4) Instantiate CCFIB in VR/AR settings to enhance engagement with virtual environments, develop VR/AR as a ‘training platform’ in clinical and recreational contexts and to demonstrate how reactions to rapid threats fluctuate with cardiac cycle, motivating corresponding changes in sensitivity of user interfaces (e.g. brakes).'